MTOR and systemic lupus erythematosus: mTOR inhibition with rapamycin showed immunoregulatory effects in several autoimmune disorders, such as systemic lupus erythematosus (SLE) [7,8], chronic immune thrombocytopenia (ITP) [9], type 1 diabetes [10], experimental autoimmune encephalomyelitis (EAE) [11], and Crohn’s disease [12].